WO2022173165A1 - 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 - Google Patents
흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2022173165A1 WO2022173165A1 PCT/KR2022/001709 KR2022001709W WO2022173165A1 WO 2022173165 A1 WO2022173165 A1 WO 2022173165A1 KR 2022001709 W KR2022001709 W KR 2022001709W WO 2022173165 A1 WO2022173165 A1 WO 2022173165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- black ginseng
- virus
- infection
- present
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 241000208340 Araliaceae Species 0.000 title claims abstract description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 25
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 25
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 21
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 241000711573 Coronaviridae Species 0.000 claims abstract description 24
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 229940088598 enzyme Drugs 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 102000004139 alpha-Amylases Human genes 0.000 claims description 8
- 108090000637 alpha-Amylases Proteins 0.000 claims description 8
- 229940024171 alpha-amylase Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- 101710130006 Beta-glucanase Proteins 0.000 claims description 6
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 6
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000014644 Brain disease Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 208000019423 liver disease Diseases 0.000 abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 22
- 239000000284 extract Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000027455 binding Effects 0.000 description 10
- 241000699800 Cricetinae Species 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 208000025721 COVID-19 Diseases 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- 238000002481 ethanol extraction Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 5
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- WOGWYSWDBYCVDY-UHFFFAOYSA-N 2-chlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=CC(=O)C=CC1=O WOGWYSWDBYCVDY-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 241000711443 Bovine coronavirus Species 0.000 description 2
- 241000711506 Canine coronavirus Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Definitions
- the present invention relates to a composition for preventing, improving or treating coronavirus infection using black ginseng, and more particularly, black ginseng, black ginseng extract, enzyme treatment of the extract, and prevention of coronavirus infection using fermented product of the extract as an active ingredient , to a composition for improvement or treatment.
- Corona virus is an RNA virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. in mammals and birds (Gallagher TM. et.al., Virology, 279(2):371-374, 2001) .
- porcine infectious gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV) are highly contagious viral diseases that invade the gastrointestinal tract and cause vomiting and diarrhea. It is a virus that causes significant economic loss due to dehydration and high fever, and a high mortality rate (Duarte M. et.al., J Gen Virol., 75 (Pt 5):1195-1200, 1994).
- Coronavirus disease 2019 (COVID-19), or COVID-19 caused by coronavirus is a new type of coronavirus (SARSCoV-) that has spread throughout China and around the world since it first emerged in Wuhan, China in December 2019. 2; It is a respiratory infection caused by an RNA virus belonging to Coronaviridae).
- the pathogen of COVID-19 is 'SARS-CoV-2'.
- ICTV International Commission on Classification of Viruses
- Coronavirus disease 2019 (COVID-19) disease which is currently a worldwide problem, is defined as a respiratory syndrome caused by a novel coronavirus (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection,
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- the classification of the disease is a statutory infectious disease, a first-class infectious disease, a new infectious disease syndrome, and the disease code is U07.1.
- the pathogen is SARS-CoV-2, which is an RNA virus belonging to Coronaviridae, and the transmission route so far is through droplets (saliva) or contact, spread through droplets generated when coughing or sneezing, or after touching an object contaminated with coronavirus. It is mainly transmitted by touching the nose and mouth.
- the global fatality rate due to coronavirus infection is on average about 3.4% (based on WHO, 3.5), and the fatality rate by country and age is very different, so that 6% of infected people worldwide are registered as dead. It causes mainly seriousness and death in debilitated patients, patients with underlying disease.
- Corona virus is an RNA virus with a helical structure of a single positive strand, and is composed of a total of five structural proteins. It is observed as if there is (Schoeman and Fielding, 2019). Corona virus is 27-34KB and is the most subdivided into 4 groups of zmu, alpha, beta, delta, and gamma among the existing RNA viruses, and among them, the beta group is highly infectious and virulent.
- SARS-CoV-2 invades by binding the surface S protein to angiotensin converting enzyme 2 (ACE2) of the host cell. It is characterized by the observation of viral pneumonia (Hamming et al., 2004).
- ACE2 angiotensin converting enzyme 2
- the incubation period of corona virus is 1 to 14 days (average 4 to 7 days), and as a diagnostic standard, it is diagnosed by isolating the virus from a sample or detecting a specific gene in the sample according to the test standards for diagnosis.
- Symptoms of COVID-19 include fever, malaise, cough, shortness of breath, and pneumonia, and various respiratory infections ranging from mild to severe.
- the reality is that there are no specific antiviral drugs other than conservative treatment such as fluid supplementation and antipyretic drugs, and the World Health Organization (WHO) states that even if there are antibodies to SARS-CoV-2, re-infection and coronavirus infection- 19 Announcing that there is no evidence that it can protect against infection, the importance of developing therapeutics has been highlighted.
- WHO World Health Organization
- the present inventor suppressed virus infection and replication when black ginseng infected Vero-E6 cells with SARS-CoV-2 virus while studying the effectiveness of black ginseng, and reduced body temperature and weight of hamsters infected with SARS-CoV-2.
- the present invention was completed by confirming the effect of inhibiting the replication and infection of the coronavirus by significantly inhibiting the SARS-CoV-2 spike protein binding activity in hamsters infected with SARS-CoV-2.
- the problem to be solved by the present invention is to provide a composition for preventing, alleviating or treating coronavirus infection, containing black ginseng as an active ingredient.
- the present invention is a corona virus containing as an active ingredient any one or more selected from the group consisting of black ginseng, black ginseng extract, and mixtures thereof, preferably Corona-19 virus (SARS-CoV-2) It provides a pharmaceutical composition or a health food composition for preventing, alleviating or treating infection.
- SARS-CoV-2 Corona-19 virus
- the black ginseng extract is characterized in that it is extracted using water or ethanol as an extraction solvent.
- the black ginseng extract is extracted after beta-calactosidase ( ⁇ -galactosidase), beta-glucosidase ( ⁇ -glucosidase), beta-glucanase ( ⁇ -glucanase), It is characterized in that it is treated with any one or more enzymes selected from the group consisting of alpha-amylase ( ⁇ -amylase) and cellulase (cellulase).
- the black ginseng extract is characterized in that it is fermented with lactic acid bacteria or yeast.
- the black ginseng extract is characterized in that it is fermented with lactic acid bacteria or yeast after treatment with an enzyme.
- composition of the present invention exhibits excellent antiviral activity against the coronavirus, which is a virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc., especially Corona-19 virus, prevention, improvement or It can be usefully used in medicines and foods for treatment.
- coronavirus which is a virus that causes respiratory diseases, digestive diseases, liver diseases, brain diseases, etc., especially Corona-19 virus, prevention, improvement or It can be usefully used in medicines and foods for treatment.
- Figure 2 shows the virus replication inhibitory effect on Vero-E6 host cells infected with the corona virus using the composition of the present invention.
- the present invention relates to a composition that can prevent, improve or treat coronavirus infection by using black ginseng, black ginseng extract, enzyme-treated product of black ginseng extract, fermented product of black ginseng extract, etc. as an active ingredient, and using the composition of the present invention
- Significant results were confirmed as a result of performing an infection inhibition and replication inhibition experiment for SARS-CoV-2 virus in Vero-E6 cells.
- composition of the present invention has been shown to inhibit the infection of the coronavirus in cells through the inhibition of the spike protein binding activity of SARS-CoV-2, which prevents, improves, or improves the therapeutic effect of coronavirus infection without toxicity. It suggests that it is effective as a therapeutic composition.
- the present invention provides a pharmaceutical composition for preventing or treating corona virus infection comprising black ginseng extract as an active ingredient.
- the 'coronavirus' is a swine infectious gastroenteritis virus (TGEV, transmissble gastroenteritis virus), porcine epidemic diarrhea virus (PEDV, porcine epidemic diarrhea virus), canine coronavirus (canine coronavirus), bovine coronavirus (bovine Coronavirus) , may be any one or more selected from the group consisting of Sascoronavirus (SARS-CoV) and Corona-19 virus (SARS-CoV-2).
- the present invention provides a health functional food composition for preventing or improving corona virus infection comprising black ginseng extract as an active ingredient.
- Black ginseng used in the present invention can be used without any particular limitation as long as it is widely known in the art to which the present invention belongs, and black ginseng can be used as a powder, and an extract obtained by solvent-extracting this black ginseng, preferably water or ethanol as an extraction solvent It can be used as an extract extracted by , and a mixture thereof can be used.
- the extraction method of the present invention can be used without any particular limitation as long as it is widely known in the technical field to which the present invention pertains, examples of which include heating extraction, cold extraction, reflux cooling, steam distillation, ultrasonic extraction, elution method, compression method, etc. It can be used by selecting one of the methods, and depending on the purpose, the extract may be subjected to a conventional fractionation process, and may be purified according to a conventional purification method.
- the extracted primary extract can be prepared by pulverizing the extracted primary extract through an additional process such as distillation under reduced pressure and freeze-drying or spray-drying, silica gel column chromatography, high performance liquid chromatography ), a purified fraction can be obtained through various chromatography methods such as thin layer chromatography.
- the extract can be understood as a concept including all extracts, separated compounds, fractions and purified substances obtained in each step of extraction, fractionation or purification, and dilution, concentration, and drying thereof.
- the black ginseng extract can be used by treating or fermenting it with an enzyme, and it can be used after being fermented with an enzyme.
- the enzyme used in the present invention is beta-calactosidase ( ⁇ -galactosidase), beta-glucosidase ( ⁇ -glucosidase), beta-glucanase ( ⁇ -glucanase), alpha-amylase ( ⁇ -amylase) and It is preferable that at least one selected from the group consisting of cellulase.
- the strain used for the fermentation of the present invention may be any strain known to be fermented by black ginseng, and preferably may be lactic acid bacteria or yeast.
- the preparation of the black ginseng extract used in the present invention is
- Lactic acid bacteria or yeast preferably Saccharomyces cerevisiae
- the fermentation step is performed at 20 to 40° C. for 10 to 48 hours.
- Black ginseng extract is a hot water extract, an ethanol extract, an enzyme-treated product with ⁇ -amylase after extraction, and an enzyme-treated product with ⁇ -amylase after extraction, followed by Saccharomyces crevicia. (Saccharomyces cerevisiae ) The fermented product was used.
- Saccharomyces cerevisiae Saccharomyces cerevisiae (Saccharomyces cerevisiae ) was added to the enzyme-treated extract and prepared through a fermentation step of fermenting at 30° C. for 24 hours.
- Vero-E6 cells were cultured in DMEM (-/-) and inoculated at a concentration of 5 ⁇ 10 5 cells/well in a 12 well-plate during virus infection experiments. It was cultured for 24 hours in a 37°C, CO2 incubator, the cell medium was removed, and then washed twice with 1 ⁇ PBS.
- the samples according to the present invention all exhibited excellent virus infection inhibitory effects, and in particular, showed much better results than the comparative groups remdesivir or chloroquinone phosphate.
- the samples treated with enzymes and fermented samples were more excellent, and there was no significant difference between hot water extraction and ethanol extraction.
- Vero-E6 cells were cultured in DMEM (-/-) and inoculated at a concentration of 5 ⁇ 10 5 cells/well in a 12 well-plate. 37° C., CO 2 Incubated for 24 hours in an incubator, the cell medium was removed, and then washed twice with 1 ⁇ PBS. For virus infection, SARS-CoV-2 virus was treated at a concentration of 50 pfu/well for 1 hour, and then 1.5 ml of medium containing 100 ⁇ g/ml of the sample was added to each well and reacted for 72 hours, then the results were confirmed. did.
- Remdesivir which is known to have a therapeutic effect on SARS-CoV-2 virus
- C.P chloroquinone phosphate
- the enzyme-treated sample and the fermented sample were more excellent, and there was no significant difference between the hot water extraction and the ethanol extraction.
- hamsters Six-week-old hamsters were obtained, randomized groups were set, and after stabilization for a week, the hamsters were infected with SARS-CoV-2, and the sample was orally administered at a concentration of 100 mg/kg after 24 hours for 4 days. Before and after virus administration, for 4 days, body weight was measured every day, and body temperature was measured once before and after infection.
- the sample according to the present invention exhibited an effect of inhibiting the binding activity of the virus, and in particular, the enzyme-treated sample and the fermented sample were more excellent, and there was no significant difference between the hot water extraction and the ethanol extraction. didn't
- Corona Virus Infectious Disease-19 is accompanied by fever due to virus infection. Accordingly, in Test Example 3, by measuring the body temperature of the hamsters on the 0th and 4th days of infection, the effect of relieving the symptoms of coronavirus infection-19 was measured and the result is shown in Table 1.
- the body temperature increased due to the corona virus infection, but it was confirmed that the increase in body temperature was suppressed due to the administration of the sample according to the present invention. It was excellent, and there was no significant difference* between hot water extraction and ethanol extraction.
- the black ginseng extract of the present invention exhibited significant infection and replication inhibitory effects against SARS-CoV-2 virus.
- it was confirmed that there is an excellent antiviral effect by confirming the body weight, body temperature, and SARS-CoV-2 spike protein binding ability after infecting the hamster with the virus.
- black ginseng extract is predicted to inhibit corona virus by inhibiting RNA replication and inhibiting protein binding ability of SARS-CoV-2.
- the composition according to the present invention exhibits excellent antiviral activity against coronavirus, which is a virus that causes respiratory disease, digestive disease, liver disease, brain disease, etc., especially Corona-19 virus. It can be usefully used in medicines and foods for improvement or treatment.
- coronavirus which is a virus that causes respiratory disease, digestive disease, liver disease, brain disease, etc., especially Corona-19 virus. It can be usefully used in medicines and foods for improvement or treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
체온(℃) | ||
감염기간(일) | ||
0일(감염 직전) | 감염 4일 후 | |
대조군 | 39.10 ± 1.756 | 42.52 ± 1.119 |
시료 1 | 39.08 ± 1.714 | 39.54 ± 1.712 |
시료 2 | 39.10 ± 1.725 | 39.54 ± 1.744 |
시료 3 | 39.07 ± 1.734 | 39.11 ± 1.388 |
시료 4 | 39.09 ± 1.756 | 39.11 ± 1.341 |
시료 5 | 39.10 ± 1.755 | 39.08 ± 1.289 |
시료 6 | 39.10 ± 1.752 | 39.08 ± 1.356 |
체중(g) | |||||
감염기간(일) | |||||
0(감염 직전) | 1 | 2 | 3 | 4 | |
대조군 | 109.5 ±1.85 | 107.5 ±1.84 | 106.3 ±1.71 | 105.7 ±1.14 | 105.2 ±1.59 |
시료 1 | 109.8 ±1.75 | 109.2 ±1.55 | 109.5 ±1.73 | 109.5 ±1.26 | 109.6 ±1.13 |
시료 2 | 109.9 ±1.88 | 109.2 ±1.75 | 109.6 ±1.82 | 109.6 ±1.24 | 109.7 ±1.35 |
시료 3 | 109.9 ±1.49 | 109.5 ±1.23 | 109.8 ±1.71 | 109.9 ±1.15 | 109.9 ±1.25 |
시료 4 | 109.9 ±1.38 | 109.5 ±1.25 | 109.9 ±1.15 | 109.9 ±1.16 | 109.9 ±1.26 |
시료 5 | 109.9 ±1.72 | 109.6 ±1.38 | 109.9 ±1.36 | 109.9 ±1.85 | 109.9 ±1.48 |
시료 6 | 109.9 ±1.74 | 109.6 ±1.83 | 109.9 ±1.31 | 109.9 ±1.85 | 109.9 ±1.45 |
Claims (7)
- 흑삼, 흑삼 추출물 및 이들의 혼합물로 이루어진 군에서 선택되는 어느 하나 이상을 유효성분으로 함유하는 코로나 바이러스 감염의 예방, 경감 또는 치료용 약학적 조성물.
- 흑삼, 흑삼 추출물 및 이들의 혼합물로 이루어진 군에서 선택되는 어느 하나 이상을 유효성분으로 함유하는 코로나 바이러스 감염의 예방 또는개선용 건강식품 조성물.
- 제 1항 또는 제 2항에 있어서, 상기 코로나 바이러스가 코로나-19 바이러스(SARS-CoV-2)인 것을 특징으로 하는 조성물.
- 제 1항 또는 제 2항에 있어서, 상기 흑삼 추출물이 물 또는 에탄올을 추출 용매로 하여 추출한 것임을 특징으로 하는 조성물.
- 제 4항에 있어서, 상기 흑삼 추출물이 추출한 후 베타-칼락토시다제(β-galactosidase), 베타-글루코시다제(β-glucosidase), 베타-글루카나제(β-glucanase), 알파-아밀라제(α-amylase) 및 셀룰라제(cellulase)로 이루어진 군에서 선택되는 어느 하나 이상의 효소로 처리한 것임을 특징으로 하는 조성물.
- 제 4항에 있어서, 상기 흑삼 추출물이 추출한 후 유산균 또는 효모로 발효한 것임을 특징으로 하는 조성물.
- 제 5항에 있어서, 상기 흑삼 추출물이 효소로 처리로 처리한 후 유산균 또는 효모로 발효한 것임을 특징으로 하는 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/275,643 US20240123011A1 (en) | 2021-02-09 | 2022-02-03 | Composition containing black ginseng as active ingredient for prevention, alleviation, or treatment of coronavirus infection |
CN202280026541.4A CN117279652A (zh) | 2021-02-09 | 2022-02-03 | 含黑参有效成分的预防、改善或治疗冠状病毒感染的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210018096A KR102503431B1 (ko) | 2021-02-09 | 2021-02-09 | 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 |
KR10-2021-0018096 | 2021-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022173165A1 true WO2022173165A1 (ko) | 2022-08-18 |
Family
ID=82838219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/001709 WO2022173165A1 (ko) | 2021-02-09 | 2022-02-03 | 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240123011A1 (ko) |
KR (1) | KR102503431B1 (ko) |
CN (1) | CN117279652A (ko) |
WO (1) | WO2022173165A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240037390A (ko) * | 2022-09-13 | 2024-03-22 | 주식회사 진생바이팜 | 인삼류 추출물 및 스테로이드계 화합물을 유효 성분을 함유하는 항바이러스 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120061442A (ko) * | 2010-12-03 | 2012-06-13 | 안준민 | 흑삼 제조방법 |
KR20180013792A (ko) * | 2016-07-29 | 2018-02-07 | 주식회사 셀투인 | 점막용 항인플루엔자 바이러스 조성물 |
KR102173159B1 (ko) * | 2019-05-20 | 2020-11-03 | 씨제이제일제당 (주) | 흑삼 추출물을 포함하는 항인플루엔자 바이러스 조성물, 호흡기 질환 치료용 조성물 및 항노화 조성물 |
CN112007106A (zh) * | 2020-08-31 | 2020-12-01 | 山东省现代中药研究院有限公司 | 一种辅助预防covid-19的发酵组合物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101834872B1 (ko) | 2016-09-09 | 2018-04-13 | 주식회사 제넨셀 | 담팔수 추출물 또는 이의 분획물을 유효 성분으로 포함하는 알파 계열 허피스 바이러스 감염증의 예방 또는 치료용 약제학적 조성물 |
-
2021
- 2021-02-09 KR KR1020210018096A patent/KR102503431B1/ko active IP Right Grant
-
2022
- 2022-02-03 WO PCT/KR2022/001709 patent/WO2022173165A1/ko active Application Filing
- 2022-02-03 US US18/275,643 patent/US20240123011A1/en active Pending
- 2022-02-03 CN CN202280026541.4A patent/CN117279652A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120061442A (ko) * | 2010-12-03 | 2012-06-13 | 안준민 | 흑삼 제조방법 |
KR20180013792A (ko) * | 2016-07-29 | 2018-02-07 | 주식회사 셀투인 | 점막용 항인플루엔자 바이러스 조성물 |
KR102173159B1 (ko) * | 2019-05-20 | 2020-11-03 | 씨제이제일제당 (주) | 흑삼 추출물을 포함하는 항인플루엔자 바이러스 조성물, 호흡기 질환 치료용 조성물 및 항노화 조성물 |
CN112007106A (zh) * | 2020-08-31 | 2020-12-01 | 山东省现代中药研究院有限公司 | 一种辅助预防covid-19的发酵组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
YI, YEONG-DEUK: "Immune Functional Properties of Korean (Red) Ginseng as a Traditional Food", FOOD INDUSTRY AND NUTRITION, KR, vol. 25, no. 1, 1 January 2020 (2020-01-01), KR, pages 1 - 10, XP009538989, ISSN: 1226-3338 * |
Also Published As
Publication number | Publication date |
---|---|
CN117279652A (zh) | 2023-12-22 |
KR102503431B1 (ko) | 2023-02-27 |
KR20220115677A (ko) | 2022-08-18 |
US20240123011A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022050516A1 (ko) | 담팔수 추출물을 유효성분으로 포함하는 코로나 바이러스 치료제 | |
WO2022173165A1 (ko) | 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 | |
WO2018135843A2 (ko) | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물 | |
WO2019004668A1 (ko) | 프로테우스 속 세균 유래 나노소포 및 이의 용도 | |
WO2018043874A1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2017200192A1 (ko) | 항바이러스 활성을 가지는 사료 첨가제 조성물 | |
WO2021230581A1 (ko) | 신규한 아커만시아 뮤시니필라 ak32 균주의 발견 및 장 손상의 예방 또는 치료를 위한 응용 | |
WO2022131603A1 (ko) | 현초 추출물을 유효성분으로 포함하는 항바이러스 조성물 | |
KR20230040961A (ko) | 테트란드린 또는 이의 유사체를 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022065983A2 (ko) | 돌외 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022220339A1 (ko) | 오배자 추출물을 유효성분으로 포함하는 코로나 바이러스(sars-cov-2) 감염의 예방 또는 치료용 조성물 | |
WO2022065972A2 (ko) | 음양곽 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022065971A2 (ko) | 지구자 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
KR20230083894A (ko) | 햄프씨드와 흑삼 추출물을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 | |
WO2019164230A1 (ko) | 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도 | |
WO2022154542A1 (ko) | 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법 | |
WO2022131604A1 (ko) | 상지 유래 화합물을 유효성분으로 포함하는 항바이러스 조성물 | |
WO2020171256A1 (ko) | 클로스트리디움 디피실레(clostridium difficile) 성장 억제효과를 갖는 락토바실러스 균주 | |
WO2021235695A1 (ko) | 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물 | |
WO2023149725A1 (ko) | 코비드-19 항바이러스제 | |
WO2022215827A1 (ko) | Sars-cov-2 3cl 프로테아제와 rdrp활성을 억제하는 지유 추출 조성물 | |
WO2022146070A1 (ko) | B형 간염 바이러스 유래 폴리펩티드를 포함하는 항 코로나 바이러스용 약학적 조성물 | |
WO2024019492A1 (ko) | 폐 오가노이드를 이용한 covid-19 및 호흡기 질환 바이러스 감염 모델 | |
WO2024085623A1 (ko) | 항염증 효능이 있는 락티플랜티바실러스 플란타룸 km2 균주 발효 배양상등액의 마이크로바이옴 조성물 | |
WO2022085806A1 (ko) | 코로나바이러스 감염 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752925 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18275643 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280026541.4 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22752925 Country of ref document: EP Kind code of ref document: A1 |